CANCER CHEMOTHERAPY ASSOCIATED NAUSEA AND VOMITING THERAPEUTICS MARKET ANALYSIS

Chemotherapy-induced nausea and vomiting (CINV)  is one of the most serious and dreaded adverse effects of cancer treatment . Up to 70%–80% of patients have been said to have the condition. Antiemetics often have less success reducing nausea, and the incidence of nausea is typically higher than that of real vomiting. There are several different types of CINV, including anticipatory, acute, delayed, breakthrough, and refractory. Chemotherapeutic regimens can be grouped into those with high, moderate, low, or little emetogenicity risk. The frequency and timing of CINV varies depending on the patient's characteristics and the chemotherapeutic drugs. Weakness, weight loss, dehydration, anorexia, a reduction in mental state, as well as a number of other issues, can be serious side effects of CINV. Emesis and nausea are still common side effects of chemotherapy, despite the emergence of more potent antiemetic medications. For the benefit of patients, it is crucial to understand the mechanism behind CINV, recognize those who are more at risk, and discover and develop efficient antiemetic therapies. This field of research is still quite active.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Million in 2023, exhibiting a CAGR of 5.7% during the forecast period (2023-2030).

Analysts’ Views on Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market growth can be hindered by high cost of chemotherapy-induced nausea and vomiting (cinv) treatment drugs. For instance, according to GoodRx, Inc., a healthcare company that operates a telemedicine platform and a free-to-use website and mobile app that track prescription drug prices in the U.S., the average retail price of 1 capsule Akynzeo (Netupitant and Palonosetron Capsules) is around US$ 570.8.

Figure 1. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (%), By Type, 2023

To learn more about this report, request a free sample copy

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market– Drivers

Rising Cancer Prevalence will Increase the Number of Chemotherapies

Rising cancer prevalence will increase the number of chemotherapies is expected to drive the global cancer chemotherapy associated nausea and vomiting therapeutics market growth over the forecast period. For instance, according to the data provided by the World Health Organization, in February 2022, the most common types of cancer were breast cancer accounting for 2.26 million cases and lung cancer accounting for 2.21 million cases in the year 2020, globally. Moreover, according to the data provided by the World Health Organization in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Figure 2. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (US$ Million), By Region, 2023

To learn more about this report, request a free sample copy

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market over the forecast period. North America holds 44.6% of the market share, due to increasing adoption of inorganic strategies such as distribution and supply agreements by key players in North America region. For instance, in May 2022, Knight Therapeutics Inc., a Canada-based specialty pharmaceutical company, through one of its wholly-owned subsidiaries, and Helsinn Healthcare SA, a global biopharma company, announced that they had entered into an exclusive license, distribution, and supply agreement for AKYNZEO oral/IV (netupitant/palonosetron/ fosnetupitant/palonosetron) in Canada, Brazil, Argentina, Uruguay, and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. AKYNZEO is 5-HT3 and NK1 receptor antagonist fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. ALOXI solution for injection is marketed in Canada for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy and highly emetogenic cancer chemotherapy, including high-dose cisplatin in adults. Under the terms of the agreement, Knight Therapeutics Inc. will have the exclusive right to distribute, promote, market, and sell the products in the licensed territories.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative economic impact on the global cancer chemotherapy associated nausea and vomiting therapeutics market, owing to interruption in the people visits to the hospitals due to lockdown and decreasing cancer diagnosis rates. For instance, according to a data published, in August 2020, by Cancer Connect, during the COVID-19 pandemic, globally there was 46% decrease in the diagnoses of six most common cancer types-breast, colorectal, lung, pancreatic, gastric, and esophageal cancers.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Segmentation

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market  is segmented into Type, Drug Class, Route of Administration and Distribution Channel

Based on Type, the market is segmented into acute CINV, delayed CINV, anticipatory nausea and emesis, breakthrough CINV/refractory CINV. Out of which, the delayed CINV segment is expected to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period, owing to increasing research and development activities for delayed CINV.

Based Drug Class, the market is segmented into dopamine receptor antagonists, serotonin (5-HT3) receptor antagonists, substance P/NK-1 antagonists, corticosteroids and others. Out of which, the serotonin (5-HT3) receptor antagonists segment is expected to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period, owing to Increasing launches of serotonin (5-HT3) receptor antagonists.

Based Route of Administration, the market is segmented into oral, parenteral  and transdermal patch. Out of which, the oral segment is expected to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period, owing to increasing oral drug launches to treat CINV.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period, owing to launching pharmacies.

Among all segmentation, the delayed CINV segment has the highest potential due to increasing research and development activities.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Cross Sectional Analysis

Among end user, Hospital Pharmacies segment hold a dominant position in North America Region. Hospitals are focused on launching pharmacies, which is expected to drive the segment growth over the forecast period. For instance, in September 2022, Apollo Pharmacy, a part of The Apollo Hospitals Group, announced the launch of its 5,000th store in India, which is situated at Perungudi, Old Mahabalipuram Road in Chennai

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Key Developments

In May 2021, Tetra Bio-Pharma Inc., a company involved in cannabinoid-derived drug discovery and development, announced that the company had been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft gel capsules in Canada. REDUVO is a synthetic tetrahydrocannabinol-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy.

In September 2020, Sandoz announced the launch of generic antiemetic medicine Fosaprepitant injection 150 mg in the U.S., enhancing hospital offerings and strategically expanding its injectables portfolio. Fosaprepitant is an antiemetic drug used in adults for the prevention of nausea and vomiting associated with certain chemotherapies.

In December 2020, Jupiter Wellness, Inc., a pharmaceutical company, signed a definitive agreement to merge with Next Frontier Pharmaceuticals, Inc., a drug developer and manufacturer of synthetic cannabinoid pharmaceuticals. Next Frontier Pharmaceuticals owns the only U.S. FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid, SYNDROS, used in adults to treat chemotherapy-induced nausea and vomiting.

In February, 2020, Camber Pharmaceuticals Inc., a fully integrated international pharmaceutical company, announced the launch of Dronabinol capsules to its portfolio of products. Dronbinol is used to treat nausea and vomiting caused by cancer chemotherapy.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market : Key Trends

Increasing Government Intiatives for Improving Cancer Care

Increasing government initiatives to establish cancer care centers is expected to drive the global cancer chemotherapy associated nausea and vomiting therapeutics market growth over the forecast period. For instance, in August 2022, the Prime Minister of India, Narendra Modi inaugurated Homi Bhabha Cancer Hospital & Research Centre at Mohali in Punjab, India. It is a 300-bed capacity and is equipped with modern facilities to treat all types of cancers using every available treatment modalities such as surgery, radiotherapy and medical oncology- chemotherapy, bone marrow transplant, and immunotherapy. It is a part of Pradhan Mantri Swasthya Suraksha Yojana, a program implemented by the Union Ministry of Health and Family Welfare, India, with an aim to correct imbalances in the availability of tertiary healthcare services and improve the quality of medical education.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market : Restraint

Poor Reimbursement Policies

Poor reimbursement policies and healthcare financing structures in low economies such as Middle East is expected to act as a restraint for the market growth over the forecast period. For instance, according to an article published by the European Medical Journal, in August 2020, antiemetic guidelines are valid in countries where drugs are available and reimbursed; however, this is not the case in some parts of the world.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Key Players

Major players operating in the global cancer chemotherapy associated nausea and vomiting therapeutics market are Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy’s Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.

*Definition: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of cancer treatment. Nausea and vomiting are the most feared, as well as the most common adverse effects among patients undergoing chemotherapy